Mitoconix, which is developing neurodegenerative treatments, was founded by the Johnson & Johnson and Takeda-backed FutuRx incubator.
Mitoconix Bio, an Israel-based biopharmaceutical startup that emerged from the corporate-backed FuturRx incubator, has raised $20m in an oversubscribed series A round led by venture capital firm Remiges Ventures.
Arix Bioscience, OrbiMed, Dementia Discovery Fund and RMGP Bio-Pharma Investment Fund, which invests in portfolio companies of FuturRx, also contributed capital.
Mitoconix, which was founded in 2016 by FutuRx, has obtained an exclusive licence to research conducted by professor Daria Mochly-Rosen and her team at Stanford University. It is working on…
